Download
s12872-020-01671-2.pdf 3,68MB
WeightNameValue
1000 Titel
  • Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study
1000 Autor/in
  1. Belyavskiy, Evgeny |
  2. Ovchinnikov, Artem |
  3. Potekhina, Alexandra |
  4. Ageev, Fail |
  5. Edelmann, Frank |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-10
1000 Erschienen in
1000 Quellenangabe
  • 20(1):408
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12872-020-01671-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488149/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Heart failure with preserved ejection fraction (HFpEF) is frequently complicated by pulmonary hypertension (PH). A pulmonary vascular contribution could be considered as a substantial therapeutic target in HFpEF and PH and combined pre- and postcapillary PH (Cpc-PH).!##!Methods!#!We enrolled 50 patients with HFpEF and Cpc-PH who were determined by echocardiography to have pulmonary artery systolic pressure (PASP) > 40 mmHg, pulmonary vascular resistance > 3 Wood units, and/or transpulmonary gradient > 15 mmHg.!##!Results!#!The patients were assigned to the phosphodiesterase 5 (PDE5) inhibitor sildenafil group (25 mg TID for 3 months followed by 50 mg TID for 3 months; n = 30) or the control group (n = 20). In the sildenafil group after 6 months, the 6-min walk distance increased by 50 m (95% CI, 36 to 64 m); substantial improvement in NYHA functional class and exercise capacity during diastolic stress test were revealed; decreases in early mitral inflow to mitral annulus relaxation velocities ratio by 2.4 (95% CI, - 3.3 to - 1.4) and PASP by 17.0 mmHg (95% CI, 20.4 to 13.5) were observed; right ventricular systolic function (M-mode tricuspid annular plane systolic excursion) increased by 0.42 cm (95% CI, 0.32 to 0.52 cm; P < 0.01 for all). No changes occurred in the control group.!##!Conclusions!#!In a subset of patients with HFpEF and Cpc-PH assessed by echocardiography, PDE5 inhibition was associated with an improvement in exercise capacity, pulmonary haemodynamic parameters, and right ventricular function. The role of sildenafil needs to be considered in randomized trials in selected patients with HFpEF with invasively confirmed Cpc-PH.!##!Trial registration!#!Russian National Information System of Research, Development and Technology Data of Civilian Usage (NIS, https://rosrid.ru), registration number 01201257849 . Registered 20 April 2012. This manuscript adheres to the CONSORT guidelines.
1000 Sacherschließung
lokal Sildenafil Citrate/adverse effects [MeSH]
lokal Pulmonary hypertension
lokal Stroke Volume/drug effects [MeSH]
lokal Phosphodiesterase 5 Inhibitors/therapeutic use [MeSH]
lokal Aged [MeSH]
lokal Heart Failure/diagnostic imaging [MeSH]
lokal Phosphodiesterase 5 Inhibitors/adverse effects [MeSH]
lokal Vasodilator Agents/therapeutic use [MeSH]
lokal Arterial Pressure/drug effects [MeSH]
lokal Hypertension/diagnostic imaging [MeSH]
lokal Russia [MeSH]
lokal Exercise Tolerance/drug effects [MeSH]
lokal Hypertension/drug therapy [MeSH]
lokal Male [MeSH]
lokal Sildenafil Citrate/therapeutic use [MeSH]
lokal Heart failure with preserved ejection fraction
lokal Diastolic stress test
lokal Structural Heart Diseases, Heart failure, and Congenital Disorders
lokal Research Article
lokal Female [MeSH]
lokal Recovery of Function [MeSH]
lokal Vasodilator Agents/adverse effects [MeSH]
lokal Heart Failure/drug therapy [MeSH]
lokal Heart Failure/physiopathology [MeSH]
lokal Humans [MeSH]
lokal Hypertension/physiopathology [MeSH]
lokal Ventricular Function, Right/drug effects [MeSH]
lokal Treatment Outcome [MeSH]
lokal Middle Aged [MeSH]
lokal Time Factors [MeSH]
lokal Pulmonary Artery/physiopathology [MeSH]
lokal Pilot Projects [MeSH]
lokal Sildenafil
lokal Pulmonary Artery/drug effects [MeSH]
lokal Diastolic dysfunction
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-9940-0829|https://frl.publisso.de/adhoc/uri/T3ZjaGlubmlrb3YsIEFydGVt|https://frl.publisso.de/adhoc/uri/UG90ZWtoaW5hLCBBbGV4YW5kcmE=|https://frl.publisso.de/adhoc/uri/QWdlZXYsIEZhaWw=|https://frl.publisso.de/adhoc/uri/RWRlbG1hbm4sIEZyYW5r
1000 Hinweis
  • DeepGreen-ID: d374f38879154f7f8a2993f3a26346ca ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6466114.rdf
1000 Erstellt am 2023-11-16T18:43:43.449+0100
1000 Erstellt von 322
1000 beschreibt frl:6466114
1000 Zuletzt bearbeitet 2023-12-01T03:41:26.883+0100
1000 Objekt bearb. Fri Dec 01 03:41:26 CET 2023
1000 Vgl. frl:6466114
1000 Oai Id
  1. oai:frl.publisso.de:frl:6466114 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source